

Technology Advisory Interests Register

Topic: Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Mike Chambers	TAC Committee Member	Financial	I have participated in an advisory panel for Pfizer (possible comparator company) in an unrelated disease area: prostate cancer	19/08/2025	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal
Elizabeth Thurgar	TAC Committee Member	Financial	- In the last 12 months I have worked with BMS in an unrelated indication, MDS - In the last 12 months I have worked with Pfizer in an unrelated indication, NSCLC	19/08/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Kate Ren	TAC Committee Member	Financial	I provided statistical methodology consultancy service to a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	23/08/2025	It was agreed that Kate's declaration would not prevent them from participating in discussions on this appraisal
Satish Venkateshan		Financial	Regeneron is developing Odronextamab CD20xCD3 bispecific	21/08/2025	It was agreed that Satish's declaration would prevent

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			antibody is being developed and has EMA conditional marketing authorisation to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. I work for Regeneron, pharmaceuticals/biotech company. I also own shares in the company and have stock options.		them from participating in discussions on this appraisal
Tina Garvey	TAC Committee Member	Non-financial	Retina UK has had small grants for community events from AbbVie (historical only)	27/08/2025	It was agreed that Tina's declaration would not prevent them from participating in discussions on this appraisal
Mark Bishton	Expert	Direct - financial	Honoraria and Advisory boards for AbbVie.	04/06/2025	It was agreed that Mark's declaration would not prevent them from providing expert advice to the committee
Kim Linton	Expert	Direct - financial	Since 2020 and ongoing for Abbvie and Genmab, related to the product: <ul style="list-style-type: none"> • Paid advisory boards 	11/03/2025	It was agreed that Kim's declaration would not prevent them from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> • Consultancy services • Speaker's fees • Conference travel 		providing expert advice to the committee
Zoe Drymoussi	Expert	Financial	Follicular Lymphoma Foundation has received funding from AbbVie for patient related activities. This funding has had no influence on, control of, nor input into the development of performance of the programmes.	09/09/2025	It was agreed that Zoe's declaration would not prevent them from providing expert advice to the committee